Literature DB >> 22711072

Experimental endocarditis model of methicillin resistant Staphylococcus aureus (MRSA) in rat.

Wessam Abdel Hady1, Arnold S Bayer, Yan Q Xiong.   

Abstract

Endovascular infections, including endocarditis, are life-threatening infectious syndromes. Staphylococcus aureus is the most common world-wide cause of such syndromes with unacceptably high morbidity and mortality even with appropriate antimicrobial agent treatments. The increase in infections due to methicillin-resistant S. aureus (MRSA), the high rates of vancomycin clinical treatment failures and growing problems of linezolid and daptomycin resistance have all further complicated the management of patients with such infections, and led to high healthcare costs. In addition, it should be emphasized that most recent studies with antibiotic treatment outcomes have been based in clinical settings, and thus might well be influenced by host factors varying from patient-to-patient. Therefore, a relevant animal model of endovascular infection in which host factors are similar from animal-to-animal is more crucial to investigate microbial pathogenesis, as well as the efficacy of novel antimicrobial agents. Endocarditis in rat is a well-established experimental animal model that closely approximates human native valve endocarditis. This model has been used to examine the role of particular staphylococcal virulence factors and the efficacy of antibiotic treatment regimens for staphylococcal endocarditis. In this report, we describe the experimental endocarditis model due to MRSA that could be used to investigate bacterial pathogenesis and response to antibiotic treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22711072      PMCID: PMC3471301          DOI: 10.3791/3863

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  12 in total

1.  Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model.

Authors:  Yan Q Xiong; Julie Willard; Jagath L Kadurugamuwa; Jun Yu; Kevin P Francis; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia.

Authors:  Vance G Fowler; Anita Justice; Catrin Moore; Daniel K Benjamin; Christopher W Woods; Steven Campbell; L Barth Reller; G Ralph Corey; Nicholas P J Day; Sharon J Peacock
Journal:  Clin Infect Dis       Date:  2005-02-04       Impact factor: 9.079

3.  Subcutaneous infection of methicillin resistant Staphylococcus aureus (MRSA).

Authors:  Ching Wen Tseng; Marisel Sanchez-Martinez; Andrea Arruda; George Y Liu
Journal:  J Vis Exp       Date:  2011-02-09       Impact factor: 1.355

Review 4.  Staphylococcal biofilm disassembly.

Authors:  Blaise R Boles; Alexander R Horswill
Journal:  Trends Microbiol       Date:  2011-07-23       Impact factor: 17.079

5.  gC1qR/p33 blockade reduces Staphylococcus aureus colonization of target tissues in an animal model of infective endocarditis.

Authors:  Ellinor I B Peerschke; Arnold S Bayer; Berhane Ghebrehiwet; Yan Q Xiong
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 6.  Staphylococcus aureus bacteremia and endocarditis.

Authors:  Cathy A Petti; Vance G Fowler
Journal:  Cardiol Clin       Date:  2003-05       Impact factor: 2.213

7.  Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.

Authors:  George Sakoulas; Jack Brown; Kenneth C Lamp; Lawrence V Friedrich; Kimberly C Lindfield
Journal:  Clin Ther       Date:  2009-09       Impact factor: 3.393

8.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

9.  Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.

Authors:  Pamela A Moise; Ellie Hershberger; Maria I Amodio-Groton; Kenneth C Lamp
Journal:  Ann Pharmacother       Date:  2009-07-07       Impact factor: 3.154

10.  A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics.

Authors:  Vannakambadi K Ganesh; Jose J Rivera; Emanuel Smeds; Ya-Ping Ko; M Gabriela Bowden; Elisabeth R Wann; Shivasankarappa Gurusiddappa; J Ross Fitzgerald; Magnus Höök
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

View more
  5 in total

1.  Efficacy of Novel Antistaphylococcal Ectolysin P128 in a Rat Model of Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Shankaramurthy Channabasappa; Murali Durgaiah; Ravisha Chikkamadaiah; Senthil Kumar; Amruta Joshi; Bharathi Sriram
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Maltohexaose-indocyanine green (MH-ICG) for near infrared imaging of endocarditis.

Authors:  Kiyoko Takemiya; Joachim J Røise; Maomao He; Chung Taing; Alexander G Rodriguez; Niren Murthy; Mark M Goodman; W Robert Taylor
Journal:  PLoS One       Date:  2021-03-01       Impact factor: 3.240

3.  Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics.

Authors:  Nagendra N Mishra; Cassandra Lew; Wessam Abdelhady; Christian K Lapitan; Richard A Proctor; Warren E Rose; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

Review 4.  Model systems for the study of Enterococcal colonization and infection.

Authors:  H M Sharon Goh; M H Adeline Yong; Kelvin Kian Long Chong; Kimberly A Kline
Journal:  Virulence       Date:  2017-05-04       Impact factor: 5.882

5.  Piperacillin enhances the inhibitory effect of tazobactam on β-lactamase through inhibition of organic anion transporter 1/3 in rats.

Authors:  Shilei Yang; Zhihao Liu; Changyuan Wang; Shijie Wen; Qiang Meng; Xiaokui Huo; Huijun Sun; Xiaodong Ma; Jinyong Peng; Zhonggui He; Kexin Liu
Journal:  Asian J Pharm Sci       Date:  2018-12-07       Impact factor: 6.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.